Trials / Completed
CompletedNCT00092196
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 820 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0869, aprepitant / Duration of Treatment: 3 days |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2004-12-01
- Completion
- 2004-12-01
- First posted
- 2004-09-24
- Last updated
- 2017-05-05
Source: ClinicalTrials.gov record NCT00092196. Inclusion in this directory is not an endorsement.